# Eli Lilly invests additional $450M to expand RTP manufacturing site

Eli Lilly announced a $450 million investment to expand its Research Triangle Park facility in North Carolina, adding parenteral filling, device assembly and packaging capacity for incretin diabetes drugs. The expansion will create at least 100 jobs and is expected to be fully operational in 2027.

- Type: Expansion
- Announced: 2023-01-24
- Where: Research Triangle Park, North Carolina, United States
- Value: $450.0M
- Jobs: 100
- Starts operating: 2027
- Status: announced
- Products: parenteral filling, device assembly, packaging, incretin diabetes drugs
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Eli Lilly and Company](https://endata.com/companies/16522.md)

## Sources

- [prnewswire.com](https://www.prnewswire.com/news-releases/lilly-plans-to-invest-additional-450-million-at-manufacturing-site-in-research-triangle-park-301728593.html), 2023-01-24: "Expanding our operations at Research Triangle Park will accelerate the rate at which we can produce medicines that patients rely on to address serious health challenges like diabetes."
- [ncbiotech.org](https://www.ncbiotech.org/news/lilly-adds-450m-100-job-expansion-rtp-manufacturing-campus), 2023-01-24: "Expanding our operations at Research Triangle Park will accelerate the rate at which we can produce medicines that patients rely on to address serious health challenges like diabetes."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.